DCT

Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023

Retrieved on: 
Tuesday, April 18, 2023

Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.

Key Points: 
  • Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.
  • Avance Clinical was recently identified by GlobalData as a global leader in DCT technology.
  • The Evolution Summit is an invitation-only, premium forum bringing leading clinical research executives and innovative solution providers.
  • https://www.avancecro.com/avance-clinical-north-america-operations/
    - For more information about the benefits of running your next study with Avance Clinical contact us: [email protected]

Customer Award Winners Unveiled at Medidata NEXT Conference

Retrieved on: 
Thursday, March 30, 2023

Medidata , a Dassault Systèmes company, honored life sciences industry innovators and two inspirational leaders during its NEXT conference.

Key Points: 
  • Medidata , a Dassault Systèmes company, honored life sciences industry innovators and two inspirational leaders during its NEXT conference.
  • A highly anticipated feature at the event, the Medidata NEXT Awards recognize excellence in collaboration, sustainability, digital innovation, and patient leadership.
  • The ICON Medical Imaging division partnered with Medidata to deliver several successful studies for sponsors, including a large megastudy.
  • Please see the full schedule of Medidata NEXT Global conferences on the Medidata website.

Everest Group Declares 'The Age of Decentralized Clinical Trials Has Begun'

Retrieved on: 
Wednesday, March 29, 2023

DALLAS, March 29, 2023 /PRNewswire-PRWeb/ -- Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component. Everest Group predicts that the adoption of DCTs by pharmaceutical companies will rapidly accelerate as early adopters praise the approach for putting patient experience at the forefront.

Key Points: 
  • Everest Group also joins DTRA, offering members accessibility to pioneering research on clinical technology
    DALLAS, March 29, 2023 /PRNewswire-PRWeb/ -- Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component.
  • These findings and more are detailed in the Decentralized Clinical Trials Adoption Playbook .
  • Everest Group also released today its 2023 Life Sciences Decentralized Clinical Trial Platforms State of the Market Report , which analyzes the current state of the DCT market.
  • Everest Group also announced today that it has joined the Decentralized Trials Research Alliance (DTRA) to support the organization's mission of advancing policies, research practices and new technologies to make clinical trial participation widely accessible.

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 22, 2023

Several FDA-approved neoadjuvant therapies exist for ER- breast cancers, but few exist for ER+ patients, which account for approximately 78% of breast cancers.

Key Points: 
  • Several FDA-approved neoadjuvant therapies exist for ER- breast cancers, but few exist for ER+ patients, which account for approximately 78% of breast cancers.
  • We expect to enroll approximately 175 patients at up to 25 sites across the United States.
  • Continued Enrollment in Phase 2 Karisma-Endoxifen Study – The Karisma-Endoxifen study is our randomized, double-blind, placebo-controlled trial of healthy, pre-menopausal women with increased breast density.
  • Our investment totaled $4.7 million and resulted in Atossa owning approximately 19% of the outstanding capital stock of DCT.

Surging Power and Precise Control: GAC MOTOR EMPOW Officially Released in Saudi Arabia

Retrieved on: 
Wednesday, March 15, 2023

GUANGZHOU, China, March 15, 2023 /PRNewswire/ -- On 14 March, GAC MOTOR launched EMPOW, a sporty sedan featuring cutting-edge design and innovations, in Saudi Arabia.

Key Points: 
  • GUANGZHOU, China, March 15, 2023 /PRNewswire/ -- On 14 March, GAC MOTOR launched EMPOW, a sporty sedan featuring cutting-edge design and innovations, in Saudi Arabia.
  • Football star and GAC MOTOR Saudi Arabia brand ambassador Salem Al-Dawsari sent his greetings remotely via video.
  • "Saudi Arabia is one of the most important strategic markets for GAC MOTOR in the Middle East," said Zeng.
  • "We will seize the opportunity of in-depth cooperation between China and Saudi Arabia to fully promote the development of Saudi Arabia's market."

Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice

Retrieved on: 
Tuesday, March 14, 2023

BERWYN, Pa. and NEW YORK, March 14, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance and ProofPilot, the industry's first digital protocol automation platform for clinical trial, today announced a strategic partnership to further advance clinical trial operations for life science customers. Through this partnership, Mural Health's Mural Link™ platform and ProofPilot's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.

Key Points: 
  • Through this partnership, Mural Health's Mural Link™ platform and ProofPilot 's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.
  • Rigorous participant compliance in research is driven by the ability to responsibly incentivize successful and timely completion of specific tasks.
  • "We are excited to partner with ProofPilot, creating a complementary, next generation digital protocol automation ecosystem to deliver a wide variety of integrated functions to our mutual customers."
  • "At ProofPilot, we have always seen a higher degree of patient compliance when payments can be automated and closely tied to a wide variety of tasks.

Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice

Retrieved on: 
Tuesday, March 14, 2023

BERWYN, Pa. and NEW YORK, March 14, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance and ProofPilot, the industry's first digital protocol automation platform for clinical trial, today announced a strategic partnership to further advance clinical trial operations for life science customers. Through this partnership, Mural Health's Mural Link™ platform and ProofPilot's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.

Key Points: 
  • Through this partnership, Mural Health's Mural Link™ platform and ProofPilot 's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.
  • Rigorous participant compliance in research is driven by the ability to responsibly incentivize successful and timely completion of specific tasks.
  • "We are excited to partner with ProofPilot, creating a complementary, next generation digital protocol automation ecosystem to deliver a wide variety of integrated functions to our mutual customers."
  • "At ProofPilot, we have always seen a higher degree of patient compliance when payments can be automated and closely tied to a wide variety of tasks.

SHAREHOLDER ALERT: Weiss Law Reminds ARGO, OSH, WAYN, and DCT Shareholders About Its Ongoing Investigations

Retrieved on: 
Thursday, March 9, 2023

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Argo Group International Holdings, Ltd. (NYSE: ARGO), in connection with the proposed acquisition of ARGO by Brookfield Reinsurance Ltd.

Key Points: 
  • Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Argo Group International Holdings, Ltd. (NYSE: ARGO), in connection with the proposed acquisition of ARGO by Brookfield Reinsurance Ltd.
  • Under the terms of the merger agreement, ARGO shareholders will receive $30.00 in cash for each share of ARGO common share owned.
  • Under the terms of the merger agreement, OSH shareholders will receive $39.00 in cash for each share of OSH common stock owned.
  • Under the terms of the merger agreement, DCT shareholders will receive $19.00 in cash for each share of DCT common stock owned.

Curebase Selected Among Y Combinator's Top Private Companies of 2023

Retrieved on: 
Tuesday, March 7, 2023

SAN FRANCISCO, March 7, 2023 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, announced today that it has been named among Y Combinator's 2023 Top Private Companies, placing among the top 6% of all companies that appeared on the list.

Key Points: 
  • DCT platform company places in top 6% of private companies; recognized for end-to-end clinical trial execution built on cutting-edge software
    SAN FRANCISCO, March 7, 2023 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, announced today that it has been named among Y Combinator's 2023 Top Private Companies, placing among the top 6% of all companies that appeared on the list.
  • "We're delighted to be included among the prestigious companies in Y Combinator's 2023 Top Private Companies list, and are grateful to Y Combinator for the recognition," said Tom Lemberg, CEO, Curebase.
  • "Curebase runs decentralized studies that reach any patient, anywhere, to enable trials that were not possible before.
  • Additionally, in 2022, Curebase launched 21 new studies, enrolled 5,824 patients in clinical trials, enabled 10,643 site visits, and reached 4,111 zip codes for patient prescreening.

ObvioHealth, IQVIA Consumer Health, and Jovie USA Launch Innovative At-Home Trial to Bring First Goat Milk-Based Infant Formula to the United States

Retrieved on: 
Tuesday, March 7, 2023

NEW YORK, March 7, 2023 /PRNewswire/ -- ObvioHealth, in partnership with IQVIA Consumer Health, announces the launch of a fully decentralized clinical trial with Jovie USA to bring the first FDA-approved goat milk-based infant formula to the United States. The innovative study design is the first of its kind for infant formula, allowing parents and their newborns to participate in the trial from their homes without the need for in-clinic visits. ObvioHealth and Jovie involved the FDA in the design of the study to increase the probability of regulatory success upon the completion of the trial. 

Key Points: 
  • The fully decentralized clinical trial was designed with guidance from the FDA, which is anticipated to fast-track approval for Jovie USA's goat milk-based formula.
  • NEW YORK, March 7, 2023 /PRNewswire/ -- ObvioHealth , in partnership with IQVIA Consumer Health, announces the launch of a fully decentralized clinical trial with Jovie USA to bring the first FDA-approved goat milk-based infant formula to the United States.
  • ObvioHealth and Jovie involved the FDA in the design of the study to increase the probability of regulatory success upon the completion of the trial.
  • For more information about Jovie USA's goat milk-based formula, visit www.jovieusa.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/obviohealth-iqvia-consumer-heal...